Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
10.3(c) 10.35(c) 10.25(c) 10.35(c) 10.55(c) Last
459 401 409 622 360 538 378 919 371 855 Volume
-3.74% +0.49% -0.97% +0.98% +1.93% Change
More quotes
Financials ($)
Sales 2017 251 M
EBIT 2017 64,9 M
Net income 2017 -151 M
Debt 2017 262 M
Yield 2017 -
Sales 2018 254 M
EBIT 2018 99,9 M
Net income 2018 53,2 M
Debt 2018 155 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 12,46
EV / Sales2017 3,00x
EV / Sales2018 2,55x
Capitalization 492 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products.It operates through the following geographic segments: Asia, the Americas, and Europe.It offers Lubiprostone, which treats... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
11/16 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
11/09 Sucampo to Host 2017 R&D Day on November 16 in New York
11/07 SUCAMPO PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/02 SUCAMPO PHARMACEUTICALS : Results of Operations and Financial Condition, Financi..
11/01 SUCAMPO PHARMACEUTICALS, INC. : Class A to Host Earnings Call
11/01 SUCAMPO PHARMACEUTICALS : tops 3Q revenue forecasts
11/01 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/01 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
11/01 Sucampo Reports Third Quarter 2017 Financial Results
10/25 SUCAMPO PHARMACEUTICALS : Announces Third Quarter 2017 Earnings Call
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
SUCAMPO PHARMACEUTICALS - 2015
The bullish trend is not over
BUY
More Strategies
News from SeekingAlpha
11/14 Premarket analyst action - healthcare
11/01 Magic Formula Investing Companies Vs. The Most Traded Companies In The U.S. M..
11/01 Sucampo Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides
11/01 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q3 2017 Results - Earn..
11/01 Sucampo beats by $0.02, beats on revenue
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 16,1 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Maureen E. O'Connell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.-22.14%492
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805